Gbola Amusa

Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing

Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data

Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data

Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

6 Gene Therapy M&A Targets On The Radar

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

6 Gene Therapy M&A Targets On The Radar

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Chardan: Tocagen's Brain, Spinal Cord Tumor Candidate Has $877M Potential

Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst

Gbola Amusa Recent News

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate

Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson

Analyst: AveXis M&A Could Support Interest In Regenxbio

Chardan: Why The Novartis-AveXis Acquisition Is Good News For The Gene Therapy Space

Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy

Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product

After A Freefall In Axovant Shares, Chardan Upgrades

There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials

Expect More Downside In Axovant Sciences

Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing

Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst

La Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process

Why Ionis Results Today Support A Pair Trade With Alnylam

AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients

Chardan Analyst Suggests An AveXis-Ionis Pair Trade

Here's What Makes La Jolla Pharma A 2017 Top Pick At Chardan

Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April

5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward

The Medicines Co. Is A Top Pick For 2017

Why The Biogen-Ionis News Is A Boon For AveXis